News

Home Run Biotechnology Co., Ltd.in collaboration with Hualien Tzu Chi Medical Center and the National Defense Medical University to unveil years of dedicated research, showcasing groundbreaking achievements in integrative cancer medicine and orthopedic regenerative therapy.

The event gathered numerous experts, scholars, PhDs, physicians, and leading media outlets, all witnessing the remarkable potential of the patented “Ginkgo-Cultivated Cordyceps” in anti-cancer, anti-viral activity, and its rich content of fungal exosomes.

An exciting announcement was also made during the event —
Home Run Biotechnology officially obtained its listing on the GISA Plus Board under the “Biotech and Medical Care” category in October 2025, with stock code 7695.

Staying true to its mission of natural, plant-based, and scientifically validated innovation, the company continues to advance the vision of Precision Nutrition, bringing new hope to the field of preventive medicine.